Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2003
12/04/2003WO2003099273A1 Adduct of topiramate and tramadol hydrochloride and uses thereof
12/04/2003WO2003099269A1 Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
12/04/2003WO2003099267A1 Medicament with delayed release of the active substance, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
12/04/2003WO2003099265A2 Pharmaceutical active substance combination and the use thereof
12/04/2003WO2003099256A2 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES)
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003099011A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003082196A3 Combination therapy using trefoil peptides
12/04/2003WO2003080841A8 Calcineurin activators
12/04/2003WO2003075921A3 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/04/2003WO2003072062A3 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/04/2003WO2003070728A3 Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003066604A3 Novel aryl- and heteroarylpiperazines
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003063846A3 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
12/04/2003WO2003057898A8 Methods and materials for modulating p2x2
12/04/2003WO2003057380A3 Compositions including ammonia oxidizing bacteria and methods of using same
12/04/2003WO2003057170A3 Oral insulin therapy
12/04/2003WO2003057169A3 4-dedimethylamino tetracycline compounds
12/04/2003WO2003049692A3 The use of acyl salicylates as heat shock inducers
12/04/2003WO2003046552A3 Screening method for compounds that modulate neuronal activity
12/04/2003WO2003046141A3 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
12/04/2003WO2003039540A3 D-amino acid oxidase inhibitors for learning and memory
12/04/2003WO2003039523A3 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
12/04/2003WO2003031462A3 Nogo receptor-mediated blockade of axonal growth
12/04/2003WO2003030878A3 Galenic microparticulate oral formulation
12/04/2003WO2003028709A3 Use of mannosamine derivatives for the stimulation of neurite growth
12/04/2003WO2003024406A3 Nestin-expressing hair follicle stem cells
12/04/2003WO2003022217A3 Treatment of excessive radiation (e.g. sunburn) exposure
12/04/2003WO2003017949A3 Novel synthetic ganglioside derivatives and compositions thereof
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003014145A3 Peptides that bind to atherosclerotic lesions
12/04/2003WO2003011264A3 Betacarboline derivatives as gaba a-receptor-modulators having nmda-antagonistic activity for treating diseases of the central nervous system
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2003005969A3 Tetrahydropurinones as corticotropin releasing factor
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002079471A3 Cholinesterase-anchoring protein, corresponding nucleic acids and their use for preparing medicines
12/04/2003WO2002078747A8 Pregabalin lactose conjugates
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002070708A3 Glutamate receptor modulatory proteins and nucleic acids encoding them
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002065977A3 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
12/04/2003WO2002064742A3 Compounds effecting neuron remodeling and assays for same
12/04/2003WO2002057427A3 Mammalian tumor susceptibility gene products and their uses
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003US20030225281 Piperidines derivatives and their use as serotonin receptor antagonists
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225269 Inhibitors of interleukin-1beta converting enzyme
12/04/2003US20030225266 N-aromatic or heteroaromatic-oxyalkylene, hydrocarbylnamide derivatives useful for potentiating glutamate receptor function; Alzheimer's Disease; antidepressants; cognition activators; psychosis; psychiatric and neurological disorders
12/04/2003US20030225164 Carbocyclic amines such as 4-(3-(4-Phenylcyclohexylamino)-propyl)phenol, administered as N-Methyl-D-Aspartate (NMDA) receptor inhibitors, for prophylaxis of cardiovascular, brain or nervous system disorders
12/04/2003US20030225163 Sulfonamide derivatives
12/04/2003US20030225154 Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differentail cns receptor activity and behavior
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225140 Use of 2-amino-4-heteroarylethyl-thiazoline derivatives as inhibitors of inducible no-synthase
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225133 N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith
12/04/2003US20030225130 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
12/04/2003US20030225122 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia
12/04/2003US20030225116 Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine
12/04/2003US20030225102 Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate
12/04/2003US20030225097 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
12/04/2003US20030225095 Method of affecting sleep and sleep-related behaviors
12/04/2003US20030225085 For reducing neuronal cell death in response to a traumatic event
12/04/2003US20030225084 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others.
12/04/2003US20030225080 Treating a disorder responsive to the blockade of sodium channels
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225070 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/04/2003US20030225068 Particularly useful in the treatment of depression.
12/04/2003US20030225065 Use of 4-(1,4-diazepan-1-yl)- or 4-piperazin-1-yl-2-aminophenyl phenyl sulfones for treatment of disorders of the central nervous system.
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225059 Cyclohexyl derivatives and their use as therapeutic agents
12/04/2003US20030225058 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity
12/04/2003US20030225057 3-Benzoazepine derivatives
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225038 Adenosine receptor antagonists and methods of making and using the same
12/04/2003US20030225031 Liquid or gel solution for nasal administration also containing a permeation-enhancement agent for transmucosal drug uptake.
12/04/2003US20030225002 Aminosulfonyloxymethyl-substituted pyrans or cyclohexanes (e.g., topiramate) for relieving migraines and associated symptoms (nausea, vomiting, photophobia, phonophobia, etc.) administered with an antimigraine agent
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224968 Identifying subjects who have or are at risk for developing Hereditary Spastic Paraplegia by detecting the presence or absence of one or more variations in the atlastin gene or treating HSP by administering atlastin
12/04/2003US20030224466 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/04/2003US20030224413 Comprises polynucleotides coding restriction fragment length polymorphism for use in identifying, characterizing and treatment of blood, respiratory, tumor and nervous system disorders
12/04/2003US20030224362 Diagnosing alcoholism using presence of mutation in neuropeptide y gene; drug abuse; restriction fragment length polymorphisms; immunoassay
12/04/2003US20030224072 Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions
12/04/2003US20030224051 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
12/04/2003US20030224045 Combination immediate release sustained release levodopa/carbidopa dosage forms
1 ... 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 ... 1833